Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2019

View Archived Issues

Passage Bio announces new gene therapy clinical program for infantile Krabbe disease

Promising preclinical data presented for 4D-C102 and 4D-310

Patient enrollment ongoing in phase I study of BIIB-100

Dermavant Sciences initiates phase III study of tapinarof for the treatment of plaque psoriasis

A-Alpha Bio receives grant to develop drugs for infectious diseases

Fragile X quick-ish fix?

First phase I results for anti-GITR antibody MK-4166 in patients with advanced solid tumors

DNA repair pipeline stretches from POLO to pre-preclinical

Jiangsu Hengrui Medicine's camrelizumab receives first approval in China for treatment of lymphoma

Merck & Co. identifies new IDO-1 inhibitors

EZH2 inhibitors disclosed by Constellation Pharmaceuticals

Angex Pharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

Bristol-Myers Squibb discloses integrin alphav antagonists

Respiratory syncytial virus inhibitors patented by Enanta Pharmaceuticals

Phase III studies of Xolair in chronic rhinosinusitis with nasal polyps meet coprimary endpoints

Promising antitumor activity of olaparib against heavily pretreated mCRPC with DDR gene defects

FDA responds to Oncology Venture's IND for proposed pivotal phase III study of LiPlaCis

Kite, Humanigen evaluate investigational combination therapy for lymphoma

Phase I results provided for JNJ-61186372 in non-small cell lung cancer

Avacta plans clinical trial of TMAC linker next year

Talaris presents quality-of-life data on FCR-001

Preliminary activity seen with U3-1402 in resistant EGFR-mutant non-small cell lung cancer

Gamida Cell presents clinical and translational data from phase I/II study of omidubicel

Phase II COPD study finds no effect of CHF-6001 on lung function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...